Nilsson, Karin H.
Henning, Petra
El Shahawy, Maha https://orcid.org/0000-0001-7122-1191
Nethander, Maria https://orcid.org/0000-0003-3688-906X
Andersen, Thomas Levin https://orcid.org/0000-0002-6981-7276
Ejersted, Charlotte
Wu, Jianyao
Gustafsson, Karin L. https://orcid.org/0000-0003-2082-4886
Koskela, Antti
Tuukkanen, Juha https://orcid.org/0000-0002-1723-6461
Souza, Pedro P. C. https://orcid.org/0000-0001-7266-6061
Tuckermann, Jan https://orcid.org/0000-0003-3691-275X
Lorentzon, Mattias
Ruud, Linda Engström
Lehtimäki, Terho https://orcid.org/0000-0002-2555-4427
Tobias, Jon H.
Zhou, Sirui https://orcid.org/0000-0003-4963-0815
Lerner, Ulf H.
Richards, J. Brent https://orcid.org/0000-0002-3746-9086
Movérare-Skrtic, Sofia https://orcid.org/0000-0001-7982-7438
Ohlsson, Claes https://orcid.org/0000-0002-9633-2805
Funding for this research was provided by:
Adlerbertska Stiftelserna
Academy of Finland (3322098; 286284; 117787)
Cancer Research UK
IngaBritt och Arne Lundbergs Forskningsstiftelse
Knut och Alice Wallenbergs Stiftelse
Article History
Received: 21 January 2021
Accepted: 19 July 2021
First Online: 13 August 2021
Change Date: 6 September 2021
Change Type: Update
Change Details: In the original version of this Article, the given and family names of author Maha EL Shahawy were incorrectly tagged, leading to incorrect indexing. This error has now been corrected. The PDF and HTML versions displayed the name correctly at the time of publication.
Competing interests
: J.B.R. has served as an advisor to GlaxoSmithKline and Deerfield Capital. He has received investigator-initiated grant funding from Eli Lilly, GlaxoSmithKline and Biogen for projects unrelated to this paper. M.L. has received lecture fees from Amgen, Astellas, Lilly, Meda, Renapharma, UCB Pharma, and consulting fees from Amgen, Radius Health, UCB Pharma, Renapharma, and Consilient Health. The other authors declare no competing interests.